Bristol Myers Squibb, one of the world’s largest biopharmaceutical companies, and Accenture, a global professional services ...
Amsterdam, the Netherlands Tuesday, December 16, 2025, 17:00 Hrs [IST] ...
Senores Pharmaceuticals to acquire Apnar Pharma and five ANDAs: Our Bureau, Bengaluru Tuesday, December 16, 2025, 16:45 Hrs [IST] Senores Pharmaceuticals has entered into a defini ...
Suraksha Diagnostics, in collaboration with Medikabazaar–United Imaging, launches uAcademy to advance radiology education: Our Bureau, Mumbai Tuesday, December 16, 2025, 16:30 H ...
CMRI launches Eastern India’s first comprehensive lung nodule evaluation & advanced management clinic: Our Bureau, Bengaluru ...
US FDA clears Minghui Pharma’s IND application to begin global phase ? trials of MHB018A, a subcutaneous single-domain IGF-1R antibody, in thyroid eye disease: Shanghai Tuesday, ...
Vanda Pharma submits BLA to US FDA for imsidolimab to treat generalized pustular psoriasis: Washington Tuesday, December 16, 2025, 15:00 Hrs [IST] Vanda Pharmaceuticals Inc., (Van ...
Gujarat Kidney and Super Speciality, a regional healthcare company located in Gujarat, announced that its initial public offering (IPO) for subscription from Monday, 22nd December, 2025, and closes on ...
Ascletis reports positive topline results from US phase I study of ASC50, a potential best-in-class oral small molecule IL-17 inhibitor: Hong Kong Tuesday, December 16, 2025, 14:3 ...
Global pharma major Lupin Limited (Lupin) announced that its greenhouse gas (GHG) emissions reduction targets have been officially validated by the Science Based Targets initiative (SBTi). These ...
Cynata Therapeutics completes patient enrolment in phase 2 trial of CYP-001 in adults with newly diagnosed, high risk aGvHD: Melbourne, Australia Tuesday, December 16, 2025, 14:00 ...
DPGU faculty wins Rs. 1.1 crore ICMR grant for developing advanced biomaterial for diabetic wound healing: Our Bureau, Bengaluru Tuesday, December 16, 2025, 13:50 Hrs [IST] Dnyaan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results